Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
Lutetium-177 (177Lu)-prostate specific membrane antigen (PSMA)-617 is a small-molecule radioligand therapy (RLT) drug targeting PSMA. By selectively delivering the β－ radiation emitted by 177Lu to PSMA-positive prostate cancer cells, it induces tumor cell death. The agent has been approved in multip...
I tiakina i:
| Ngā kaituhi matua: | , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Shanghai Chinese Clinical Medicine Press Co., Ltd.
2026-04-01
|
| Rangatū: | Zhongguo Linchuang Yixue |
| Ngā marau: | |
| Urunga tuihono: | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20251534 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|